TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An analysis of prospectively logged menstrual cycles found that users of combined GLP-1/GIP receptor agonists had a larger average decrease in cycle length and lower cycle variability than GLP-1-only users and nonusers. The study shows an association, not proof that the drugs caused the changes; researchers say more study is needed, including in people with polyendocrine metabolic ovarian syndrome.
An analysis of a prospective U.S. cohort linked use of a combined GLP-1/GIP receptor agonist with a larger reduction in menstrual cycle length and lower cycle variability than use of a GLP-1-only drug or no use. The findings, presented by Shruthi Mahalingaiah and colleagues at the American Society for Reproductive Medicine meeting, suggest a possible relationship with menstrual regularity but do not show that the medication caused the changes.
Among participants who reported using a combined GLP-1/GIP drug in the prior year, cycle length decreased by an average of 2.5 days. The corresponding reductions were 0.4 days among GLP-1 drug users and 0.8 days among participants who had never used either type of medication. The researchers also reported mean individual cycle variability of 6.93 days for combined-drug users, compared with 7.45 days for GLP-1 users and 7.46 days for never-users.
The analysis included 1,945 participants and 70,134 logged menstrual cycles from the Apple Women’s Health Study, a longitudinal digital cohort. Of those participants, 123 reported combined GLP-1/GIP use in the past year, 258 reported GLP-1 use, and 1,564 were never-users. Eligible participants were younger than 50, were not pregnant or lactating or using hormones, had cycles between 10 and 90 days, and had logged at least three cycles.
In a subgroup with polyendocrine metabolic ovarian syndrome (PMOS, formerly called polycystic ovary syndrome or PCOS), mean cycle variability was 5.80 days among combined-drug users, 7.34 days among GLP-1 users, and 9.45 days among never-users. The study compared reported medication use with participants’ logged cycles; it did not use sensor-based measurements. The report did not establish that every participant’s cycles became more regular or identify a direct biological mechanism.
Potential Relevance for Menstrual Health
Menstrual irregularity can matter beyond fertility. As reproductive endocrinologist Rachel Weinerman told MedPage Today, irregular periods may also signal underlying health issues. The results could prompt further research into whether metabolic treatments are associated with changes in ovulatory health, particularly for people with PMOS.
The findings are not a basis for prescribing these drugs to regulate periods. The study was observational, and the medication groups differed in some characteristics: users were older on average and had higher proportions of participants with PMOS, infertility, type 2 diabetes and hypertension than never-users. These differences, along with factors such as weight change, may affect cycle patterns. The analysis does not show whether any observed change was clinically meaningful for an individual or whether it would persist.
The question may be relevant to a large group of patients: the MedPage Today report said more than 10 million U.S. women use either a GLP-1 or combined GLP-1/GIP receptor agonist. However, the cohort analysis does not provide evidence that the drugs should be used for menstrual concerns, and treatment decisions remain matters for patients and their clinicians.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Hyperice Hypervolt Go 3 Portable Percussion Massage Gun with Carry Case
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Cycles
Earlier retrospective studies had suggested a link between these medicines and improved menstrual regularity, according to the report. Mahalingaiah and colleagues said their analysis addressed a gap by examining cycle length and variability using prospectively logged data. Participants shared menstrual records entered through Apple HealthKit and answered surveys covering medication use, demographics and medical history.
The researchers divided participants according to whether they reported GLP-1 or combined GLP-1/GIP medication use in the prior year, and whether they had PMOS. The study was not a randomized medication trial, so the groups were not assigned treatments by researchers. The only GLP-1/GIP drug identified in the source report as FDA-approved was tirzepatide, marketed as Zepbound; the analysis was not presented as a drug-by-drug comparison.
The medications act through different mechanisms, and the report described possible effects on ovulatory health through broader metabolic changes or direct ovarian effects as questions for research, not established explanations. The study’s measurements were menstrual-cycle records, rather than direct confirmation of ovulation.
“This more pronounced reduction among PMOS individuals might suggest a separate pathway that might focus on ovulatory health in addition to those metabolic parameters that support ovulation, but further research is necessary.”
— Shruthi Mahalingaiah, MD, MS, of the Harvard T.H. Chan School of Public Health, as quoted by MedPage Today
Cause and Clinical Effects Remain Unclear
The analysis found an association, not a causal effect. Because participants were not randomly assigned medication, the study cannot show whether the drugs, weight changes, underlying conditions or other differences between groups explain the cycle measurements. The report also does not specify whether participants used the same agents, doses or treatment durations.
It remains unclear whether the differences would be meaningful to patients, whether they reflect changes in ovulation, or whether they continue over time. The PMOS subgroup results are descriptive and do not establish that people with the condition will respond in the same way. The report did not provide evidence that the medications should be started, stopped or changed to address menstrual cycles.
Drug-Specific Analyses Are Planned
Mahalingaiah said future manuscripts will break down the data by particular medications. Those analyses may clarify whether the reported pattern differs among individual agents, although further research would still be needed to test cause and effect and assess clinical outcomes.
For now, the findings remain a conference-presented cohort analysis. Clinicians and patients should not treat menstrual changes as a proven benefit of incretin drugs based on these results alone. Anyone experiencing irregular periods or considering medication should discuss their health history and treatment options with a qualified clinician.
Key Questions
What did the analysis find?
Users of combined GLP-1/GIP receptor agonists had a larger average reduction in cycle length and lower measured cycle variability than GLP-1-only users and never-users. The study found an association and did not prove the medication caused the changes.
Does this mean incretin drugs treat irregular periods?
No. The analysis was not a randomized trial of treatment for menstrual irregularity. It does not establish these drugs as a treatment or support starting them for that purpose.
What is PMOS?
PMOS is the term used in the report for polyendocrine metabolic ovarian syndrome, formerly called polycystic ovary syndrome, or PCOS. The analysis reported lower mean cycle variability among combined-drug users in this subgroup, but the finding needs further study.
What happens next?
Mahalingaiah said future manuscripts will examine the data by specific medication. Further research is needed to determine whether the drugs cause menstrual changes, whether those changes reflect ovulation, and whether they matter clinically.
Source: medpagetoday.com
